U.S. Abortion Pill Regulations Fluctuating, Medical Community Worries About Impact on Patient Care
After U.S. abortion policy returned to the Supreme Court, confusion over mifepristone regulations has arisen. Healthcare providers and major medical organizations express concern that frequent legal changes are impacting medical care.
📋 Article Processing Timeline
- 📰 Published: May 10, 2026 at 15:39
- 🔍 Collected: May 10, 2026 at 16:01 (22 min after Published)
- 🤖 AI Analyzed: May 10, 2026 at 20:18 (4h 16m after Collected)
Central News Agency
(Central News Agency, New York 9th, comprehensive foreign report) After the U.S. abortion policy once again returned to the Supreme Court for review, it has caused confusion over the regulations for the abortion pill mifepristone. Healthcare providers and major medical organizations state that frequent legal changes have impacted medical care.
Agence France-Presse reported that in recent weeks, U.S. courts first restricted the use of the drug and then temporarily suspended the injunction, leading to uncertainty about whether patients can still obtain mifepristone by mail after a video consultation.
Medical professionals point out that mifepristone is an important drug for common abortion procedures and miscarriage management, and its restriction could have a serious impact on healthcare across the U.S.
Kristyn Brandi, who provides abortion medical services in New Jersey, told Agence France-Presse bluntly: "It's just dizzying."
"We know what's best for our patients, but we can't provide the relevant treatment because regulations can change every day. How can such a system be dealt with?"
On May 1st, a federal appeals court made a major ruling in favor of the anti-abortion camp, revoking measures implemented nationwide since 2021 that allowed mifepristone to be obtained by mail through telemedicine.
Shortly after, two pharmaceutical companies filed an emergency motion with the Supreme Court, asking to suspend the enforcement of the ruling to gain time for an appeal. The Supreme Court approved a one-week temporary suspension.
The justices are currently deliberating whether to further extend the temporary injunction during the litigation, which means that remote access to mifepristone temporarily remains legal, or to let the temporary injunction expire. This decision is expected to be announced on the 11th. (Editor: Chen Yu-ting) 1150510
Choose to stand with facts, your every sponsorship is the power to protect press freedom.
Download the Central News Agency 'First-Hand News' APP to grasp the latest news in real time.
The text, images, and videos on this website may not be reproduced, publicly broadcast, or publicly transmitted and used without authorization.
(Central News Agency, New York 9th, comprehensive foreign report) After the U.S. abortion policy once again returned to the Supreme Court for review, it has caused confusion over the regulations for the abortion pill mifepristone. Healthcare providers and major medical organizations state that frequent legal changes have impacted medical care.
Agence France-Presse reported that in recent weeks, U.S. courts first restricted the use of the drug and then temporarily suspended the injunction, leading to uncertainty about whether patients can still obtain mifepristone by mail after a video consultation.
Medical professionals point out that mifepristone is an important drug for common abortion procedures and miscarriage management, and its restriction could have a serious impact on healthcare across the U.S.
Kristyn Brandi, who provides abortion medical services in New Jersey, told Agence France-Presse bluntly: "It's just dizzying."
"We know what's best for our patients, but we can't provide the relevant treatment because regulations can change every day. How can such a system be dealt with?"
On May 1st, a federal appeals court made a major ruling in favor of the anti-abortion camp, revoking measures implemented nationwide since 2021 that allowed mifepristone to be obtained by mail through telemedicine.
Shortly after, two pharmaceutical companies filed an emergency motion with the Supreme Court, asking to suspend the enforcement of the ruling to gain time for an appeal. The Supreme Court approved a one-week temporary suspension.
The justices are currently deliberating whether to further extend the temporary injunction during the litigation, which means that remote access to mifepristone temporarily remains legal, or to let the temporary injunction expire. This decision is expected to be announced on the 11th. (Editor: Chen Yu-ting) 1150510
Choose to stand with facts, your every sponsorship is the power to protect press freedom.
Download the Central News Agency 'First-Hand News' APP to grasp the latest news in real time.
The text, images, and videos on this website may not be reproduced, publicly broadcast, or publicly transmitted and used without authorization.